NASA BIOTECHNOLOGY PROJECT MAY ADVANCE CANCER RESEARCH

Advanced technology development projects that may hold the key to detecting cancer while it affects only a few cells are getting underway at NASA’s Ames Research Center in California’s Silicon Valley.

NASA Ames has awarded grants totaling $1.286 million to support 11 peer-reviewed, in-house research projects. The grants are the first step in implementing a NASA/National Cancer Institute (NCI) partnership known as Fundamental Technologies for the Development of Biomolecular Sensors. Both agencies expect program research to lead to important benefits. Ames is leading NASA’s efforts in this new endeavor.

“The development of cutting-edge sensors, technologies and instruments should enable advances in biological research and human space exploration,” noted John Hines, manager of the NASA Biomolecular Physics and Chemistry Program, which administers the NASA element of the collaboration. The goal of the program is to develop new molecular signatures and ways to identify molecular indications of cancer and other diseases. “This intramural research program establishes a foundation for supporting the NASA/NCI collaboration,” Hines said. “We look forward to its swift execution and the validation of emerging biomolecular technologies for future NASA missions.” Research in biomolecular systems is expected to yield breakthrough technologies for minimally invasive health monitoring, early disease detection, and targeted delivery of medication — benefits of interest to both organizations.

Hines noted that there is considerable overlap in the needs of NASA and NCI for biomolecular sensors. NASA needs sensors for the diagnosis and treatment of injury, illness and emerging diseases in astronauts during long-duration space flights; for monitoring and control of life support systems; and for the remote sensing of signatures of life on distant planetary bodies. NCI needs technologies that will enable detection of the earliest stages of cancer and provide rapid and specific treatment.

The grants will support NASA research in biosensor development, high-resolution sampling of biological specimens, a new ultra-sensitive technique for detecting organisms and their biomarkers, and detection of microorganisms on sterilized surfaces. Awardees come from the life sciences, information technology, astrobiology and aerospace fields at Ames. The winning intramural proposals were selected from 41 received from Ames and NASA’s Jet Propulsion Laboratory (JPL), Pasadena, Calif., which received five additional grants. Dr. Darrell Jan of JPL will serve as deputy program manager.

The development of microscopic explorers that can travel through the human body in search of disease would allow NASA to monitor astronaut health in space, where medical test capabilities and communication with Earth may be limited. New technologies also could revolutionize the speed and effectiveness of basic health care on Earth through early detection, diagnosis and treatment of cancer.

The ability to identify changes such as protein expression or gene expression that will develop into cancer at a later date may enable scientists to develop therapies to attack these cells before the disease spreads. “With molecular technologies, we may be able to understand the molecular signatures within a cell using the fusion of biotechnology, nanotechnology and information technology,” Hines said. Ames is a leader in all three fields of research.

Currently, cancer can be detected only after it has developed into a tumor or has affected a large number of cells. Chemotherapy or radiation treatment can do significant damage to healthy cells far-removed from the cancer. If scientists can detect the disease before it affects a larger area, or even before the pre-cancerous cells become malignant, they may be able to design treatments that target only the affected cells, eliminating potential damage to other areas of the body.

Ames will focus on six key areas in molecular and cellular biology and associated technologies. Biomolecular sensors may someday be able to kill tumor cells or provide targeted delivery of medication. Molecular imaging may help scientists understand how genes are expressed and how they control cells. Developments in signal amplification could make monitoring and measurement of target molecules easier. Biosignatures — identification of signatures of life – offer the possibility of distinguishing cancerous cells from healthy cells. Information processing (bioinformatics) will use pattern recognition and modeling of biological behavior and processes to assess physiological conditions. Finally, molecular-based sensors and instrumentation systems will provide an invaluable aid to meeting NASA and NCI objectives.

NASA is supporting the program with $10 million over 5 years. NCI’s contribution is $10 million or more. In addition to the intramural efforts, the agencies have issued a joint extramural solicitation. Each organization will fund proposals of interest to it, with no exchange of funds between the organizations. The two agencies will jointly monitor the technical progress of all funded activities, and conduct joint reviews.

NASA’s participation in the collaboration is supported by the agency’s Office of Biological and Physical Research, which promotes basic and applied research to support human exploration of space and to take advantage of the space environment as a laboratory. “Our goal is to really make this an applied program and to facilitate the identification and incubation of these advanced technologies, and to transfer them efficiently to NASA and NCI programs.

 

Cancer Research

Evidence is mounting that selenium, a little-known trace element, can help protect against one of the most common cancers in men. Researchers at the University of Arizona have shown in preliminary studies that daily selenium supplements cut the rate of prostate cancer by more than half. Now, new research is under way to see if selenium might also help those who already have prostate cancer.
The Rev. Lester Plattner, diagnosed three years ago, decided against surgery or other radical treatment. “I just didn’t want to go through a series of shots and through radiation and anything like that,” he said. “And if the Lord wants me, he knows where I’m at, and he can get me anytime he wants me.” It is not unusual for men Plattner’s age, 79, to forgo treatment for prostate tumors. Typically, such cancers diagnosed after age 70 are slow-growing. Proponents of what doctors call “watchful waiting” reason that many older men are likely to die of other causes before their cancer ever poses a threat.
But Plattner is very much interested in improving the odds. As part of the “Watchful Waiting with Selenium” study, he is among 260 men helping researchers find whether selenium delays progression of prostate cancer. The volunteers are randomly prescribed one of four selenium dosages, or a placebo “dummy” pill, and are to be closely monitored for the five years.
“I don’t know whether I’m taking the pill or whether I’m taking sugar” says Plattner. “This is my contribution to society.” Through patient interviews, examinations and blood tests measuring PSA — an indicator of prostate cancer progression — scientists will document any side effects, good or bad, of prolonged selenium use and any differences in the rate of cancer growth across the five groups. Selenium decreases prostate cancer rate Larry Clark, Ph.D., directs the selenium and cancer projects at the University of Arizona Cancer Center. He was in charge of a landmark 10-year study showing the incidence of prostate cancer was 63 percent less among those taking daily selenium supplements.
“We’ve gone from knowing almost nothing about diet and prostate cancer to prostate cancer being the leading cancer that may be affected by diet, meaning we can do the most to prevent it if we find the right diet,” Clark said. He points out that the same study showed selenium users had markedly less lung and colorectal cancer as well. More than a thousand men volunteered for the trial. The study, published in December 1996, caught the attention of many cancer researchers interested in the role diet and nutrition might play in preventing cancer. Suddenly, Clark says, he had company in his selenium research.
“I think it was a surprise for everyone that selenium would have such a major effect on the prostate,” he said. Since then scientists have been looking for possible explanations for selenium’s apparent good effects. Clark cites a recent report describing a specific type of protein within the prostate that is very responsive to selenium intake. “This probably helps protect against oxidative damage there in the prostate.”
Selenium is a trace element found to a varying extent in soil. It enters the human diet through plants such as corn and through the meat of animals grazing on vegetation containing selenium. Products from selenium-rich soils of the Plains and Mountain States carry proportionately more selenium than those coming from the Upper Midwest, Northeast, and Florida, where selenium soil concentration is low. Grains (especially from the Great Plains), fish, organ meats and Brazil nuts tend to be high in selenium. It is often included in broad-spectrum nutritional supplements. There is no official government nutritional guideline on selenium. Typical recommendations range from 70 to 200 micrograms a day.
Holistic urology clinic looks to selenium and beyond Doctors at Columbia University in New York are also looking into selenium, as well as other nutritional supplements, for preventing and treating prostate cancer. The work is part of the University’s Center for Holistic Urology.
A four-year study is under way to see whether a low-fat, high-fiber diet with soy supplementation helps prevent a recurrence of prostate cancer in men who’ve been treated previously. The study is following 100 men who their cancerous prostates removed surgically but whose cancer was advanced enough at the time of surgery to leave them at higher than average risk of relapse.
Dr. Aaron Katz, director of the center, sees great value in the research. “Currently there is no consensus as to the optimal therapy for those patients who’ve had radical prostatectomy and who are at high risk for a return of their prostate cancer.” Katz favors research that might help reduce dependence on radiation and hormone therapy, which often cause unpleasant or dangerous side effects. “We need more options to treat patients with prostate cancer,” he says in a release issued by Columbia Presbyterian Center. “Some patients aren’t good candidates for current therapy strategies. Plus recent studies suggest that diet may play an important role in the development and recurrence of prostate cancer.”
Katz says he’s especially excited by the possibility of treating advanced prostate cancer with a combination of Chinese herbs. In a small study of men who had exhausted all conventional treatments for their cancers, the herbal cocktail called “PC-SPES” brought significant improvement for 85 percent.
Five percent of the subjects developed potentially dangerous blood clots in the legs, leading doctors to prescribe aspirin and other anti-clot medications. Despite the side effects, Katz said, the herbal therapy shows promise as a possible cancer treatment and deserves further study. Laboratory studies attribute a potent anti-cancer effect to PC-SPES in both test tube and animal experiments, he adds.
Katz says details of the study have been accepted for publication in the British Journal of Urology, although many of his colleagues remain unimpressed. “They think it is a bunch of hokeypokey, ” he says. “So did I until I started getting into it.” Self-help and supplements still not enough. Those involved in nutritional cancer research say diet supplements should not take the place of regular checkups. The American Cancer Society recommends annual physical examination of the prostate and a PSA
blood test starting at age 50. Men with a family history of prostate cancer and others at high risk, including all African- American men, are advised to begin prostate screening at age 45 or earlier depending on
individual risk factors.

BABA race for Cancer Research

This Sunday, May 19 is the 7th Annual Gerry Brown Memorial Windsurf Race hosted by the Baltimore Area Boardsailing Association.  It is also the third year we are raising money for cancer research at the Johns Hopkins Oncology Center in Baltimore (which is now known as the Sidney Kimmel comprehensive Cancer Center at Johns Hopkins). Our race will be held at Rocky Point Park in eastern Baltimore County, Maryland.  The park provides ample parking close to the sailing site and a large grassy rigging area.

The racing begins at 12 and registration starts around 10.  Fees are $10, of which 100% goes toward cancer research. As in the past, this race is sponsored by the New England Windsurfing Journal which is providing free NEWJ’s, soft drinks, and NEWJ t-shirts for first place finishers.  (We may even have a Formula fleet so Frank can get a shirt.) BABA welcomes all sailors to participate, even if you don’t want to race. This is a great way to get together for a good cause and show our support – and get into our annual NEWJ group photo.

Why waste money on cancer research charities?

The professions you listed are not dependant on car crashes at all. OTOH, thousands of vivisectors and administrators would be out of business overnight if it weren’t for their nice cushy jobs pretending they’ll find a cure one day. My pay currently comes from moneys donated to the Imperial Cancer Research Fund. I do not have a “nice cushy job pretending [I]‘ll find a cure one day”. I am contributing to research projects which are slowly revealing the mechanisms by which cell fates are determined, etc. etc.

As a body of knowledge is accumulated about the causes of cancer, we are able to assess the risks of day to day life and can advise people on the lifestyle choices which can help them to reduce the risks of developing cancer. Surely this is valuable? As we find out more about the biology of cancer, we can make more and more progress with the development of treatments. This talk of pretence is utter rubbish. Are you refusing to believe that it is now possible to treat more cancers than would be possible without the research which has taken place to date? Progress is being made. Cancer research is delivering treatments, not empty promises.

This justifies the existence of cancer research charities. This is why people give their money. It’s really quite simple.

 

VICE PRESIDENT AL GORE JOINS TOUR DE FRANCE CHAMPION LANCE ARMSTRONG TO ANNOUNCE NEW STRIDES IN CANCER RESEARCH

Washington DC — Vice President Al Gore today — joined by cancer survivor and Tour de France Champion Lance Armstrong, the Postmaster General, the Office of Personnel Management Director, and cancer survivors — announced important new strides in cancer research, directed the Office of Personnel Management to look into the advisability of giving federal employees time off for cancer and other preventative screenings, and underscored that more needs to be done.

“Lance Armstrong’s remarkable story is testament to the courage and strength of will show by all cancer patients,” said Vice President Al Gore. “We must keep working to fight this disease, and to give more people the hope that they, like Lance Armstrong, will have the chance to fulfill their greatest dreams.”

On the second anniversary of the Cancer Genome Anatomy Project (CGAP), a historic research effort he launched in 1997, Vice President Al Gore announced today that over 30,000 human genes have been identified, more than double the original goals, and announced that a new record number of Americans — 8.4 million — have survived cancer.

“This project is working to identify every major gene that predisposes someone to cancer,” Vice President Al Gore said. “It has the potential to revolutionize diagnosis and treatment, based on this simple principle: if we crack the enemy’s code, we can win the war.”

The Vice President also announced the development of “Insight Awards to Stamp Out Breast Cancer,” a new innovative breast cancer research program that uses funding from the over one hundred million stamps sold in the first year of the historic Breast Cancer Research stamp.

Specifically, the Vice President announced:

-    A NEW DIRECTIVE TO THE OFFICE OF PERSONNEL MANAGEMENT TO LOOK INTO THE ADVISABILITY OF GIVING FEDERAL EMPLOYEES TIME OFF FOR CANCER AND OTHER PREVENTIVE SCREENINGS.

The Vice President highlighted an innovative program implemented by Mayor Menino that gives city employees in Boston four hours off each year encouraging them to get cancer screenings. Today, Vice President Al Gore directed the Office of Personnel Management to look into advisability and feasibility of implementing this type of approach for the Federal workforce to encourage cancer and other preventive screenings.  He asked Director Janice LaChance to report back within 90 days.  The Vice President underscored that this will not only help encourage the 1.8 million Federal employees get these tests but set a model for the private sector as well.

 

Cancer Research UK

With regard to ”Cancer Research UK”  61 Lincolns Inn Field  WC2A 3PX

1. “Cancer Research UK” is spending around £170,000,000 annually on app. 3,000 scientists, none of whom are working on treatments using natural, holistic, curative approaches to cancer : the only way to successfully treat a cancer patient.

2. CRUK has a specific policy of not granting funds for research into “alternative” approaches to the treatment of cancer.

3. CRUK funding, as far as treatment is concerned, is directed towards patentable drugs etc.

4. CRUK are ignoring the views of holistic practitioners and the testimonies of the thousands of patients who have survived by using naturopathic therapies, after being damaged and left for dead by treatments developed by orthodox cancer research.

5. CRUK are actively promoting surgery, drugs and radiation, over 25 years after the leading US cancer statistician stated that this approach killed the patient much faster than the disease did.

6. CRUK policy on cancer causation remains in line with the ICRF statement “One of the biggest myths in recent years is that there is a cancer epidemic caused by exposure to radiation, pollution, pesticides and food additives. these factors have very little to do with the majority of cancers in this country.”  No genuine cancer research organisation would have gone out of its way to protect these industries.

7. CRUK have no research projects funded which are investigating the main causes of cancer – radiation, pollution, pesticides, food additives etc.

8. CRUK have a deliberate policy of not investigating any products of the pharmaceutical industry known to damage the immune system, thereby increasing the chances of cancer : vaccines, antibiotics, antipyretics, analgesics, steroids etc.

9. CRUK are well aware that cancer experts such as Prof. Karol Sikora have stated that a cure for cancer is not possible through orthodox cancer treatments but are still putting out statements and advertisements falsely stating that cures for cancer are being achieved by CRUK-supported treatments. These fraudulent “cures” are being achieved by misdiagnosis and by 5-year-survival being passed off as cure.

THE FAILURE IS DELIBERATE
“A solution to cancer would mean the termination of research programs, the obsolescence of skills, the end of dreams of personal glory. Triumph over cancer would dry up contributions to self-perpetuating charities. It would mortally threaten the present clinical establishment by rendering obsolete the expensive surgical, radiological and chemotherapeutic treatments in which so much money,  training and equipment is invested. The new therapy must be disbelieved, denied, discouraged and disallowed at all costs regardless of actual testing results and, preferably, without any testing at all.”  The Huston/Null Analysis

The charitable status for Cancer Research UK must be withdrawn; they are, clearly, not acting for the interests of the public, the cancer patient or the consumer.

 

REQUEST FOR PROPOSALS: $150 million available from 1995 Army Breast Cancer Research Program

From the BCRP Broad Agency Announcement (BAA) 1 June 1995

“The U. S. Army Medical Research and Materiel Command (USAMRMC), through this Broad Agency Announcement (BAA), is soliciting applications on breast cancer research.  Proposals will be sought across all areas of basic, clinical and epidemiologic research including all disciplines within the basic sciences, basic health sciences, the clinical sciences, as well as public health, economics, social sciences, psychosocial, quality care, non-conventional therapies, occupational health, nursing research, environmental concerns, and conventional therapies.  The overall objective of this funding effort is to promote research directed toward reducing the incidence of breast cancer, increasing survival rates, and improving the quality of life for those diagnosed with this disease.

This effort is intended to invigorate research in breast cancer by fostering new directions, addressing neglected issues, and bringing new investigators into the field. Interdisciplinary research and communication is encouraged, as are military/private collaborations.  Proposals addressing the needs of minority, elderly, low income, rural, and other underrepresented populations are encouraged, as are proposals to reduce the obstacles to widespread dissemination of proven detection, diagnostic, and therapeutic methods.  However, while programmatic goals are important, scientific merit is the principal criterion by which proposals will be evaluated.

The BAA reflects the intent of the Institute of Medicine (IOM) report, Strategies for Managing the Breast Cancer Research Program (1993), a report commissioned specifically for this program.  The report has not been incorporated into the BAA; the provisions of the BAA are controlling. Proposals are solicited in four major areas: research projects, training & recruitment projects, cancer center projects, and special mammography projects.  These areas and their various component award categories are described in this section, followed by a description of who may apply for awards.”

From the BCRP 95 Announcement 27 April 1995

“The U.S. Army will provide $150 million to continue the Department of Defense’s Breast Cancer Research program.  Of these monies, $20 million will be allocated for mammography efforts and $15 million will be provided for 3 institutions with dedicated breast cancer centers as described in the 1994 Defense Appropriations Act.  The remaining $115 million is designated to initiate new breast cancer research under a solicitation by the Department of the Army.”

 

OTP Breast Cancer Research

I don’t know how many of y’all know about this. I think it is a really good cause. We’re going to do it. A friend of mine who is a survivor sent this to me and I thought it more than worthwhile to send along. Raise $16 million by buying a book of stamps forward to the people in your department or the people you know at other companies.

BREAST CANCER RESEARCH

The notion that we could raise $16 million by buying a book of stamps is powerful! As you may be aware, the U.S. Postal Service recently released its new “Fund the Cure” stamp to help fund breast cancer research. The stamp was designed by Ethel Kessler of Bethesda Maryland. It is important that we take a stand against this disease that kills and maims so many of our mothers, sisters, and friends. Instead of the normal $.33 for a stamp, this one costs $.40. The additional $.07 will go to breast cancer research. A “normal” book costs $6.60. This one is only $8.00. It takes a few minutes in line at the Post Office and means so much. If all stamps are sold, it will raise an additional $16,000,000 for this vital research! Just as important as the money is our support. I urge each of you to do two things TODAY:

1.     Go out and purchase some of these stamps.

2.     E-mail your friends to do the same. Many of us know women and their families whose lives are turned upside-down by breast cancer. It takes so little to do so much in this drive.

 

Online Cancer Research Project – Volunteers Needed

This is not a solicitation for money, nor a promise of a fantastic new “miracle” cure. It is a note about a serious & exciting new approach to cancer research that any interested person who owns a computer & is connected to the Internet can participate in. Oxford University & the National Foundation for Cancer Research recently began a new research program using personal computers to advance cancer research. This program uses the “unused” processing time of personal computers to analyze explore promising anti-cancer compounds.

To participate in the program an individual downloads a small “tsr” computer program, This program loads itself into computer memory, and only activates when the computer is not being used (similar to a screensaver). It then uses this “excess” computer capacity to analyze thousands of organic molecules that may have promise as anti-cancer drugs. There are currently thousands of people involved in this effort, organized loosely into “research teams”. I have created a new research team called “Book Folk”. I would like to recruit anyone who is interested to participate in this program. You can join by logging on to the site, downloading & installing the software.

I have a personal interest in the research. Cancer has been the primary “mortality causing agent” in the deaths of much of my family and that of my wife. I would like to see more progress before my kids and grandkids add to the toll. If you would like to participate in the project, go to the web sites shown and make your own decision. I personally think it is a good project.

 

 

Cancer research/cell biol newsgroup

Hello all!  This is in response to Ola Myklebost’s message & Susan Forsburg’s reply to setting up a cancer research forum, but with a broader base to include cell biology topics in general.  I think it would be great to have a discussion group on cancer research. Susan is correct in that there are not rigid lines between cancer research and other areas of biological research. I think in a very broad, very general, even over simplistic view of cancer is that it is normal biological processes gone awry.  Anyway, I would like to see this newsgroup up and running, but I’m a little reluctant to call it cell-biol.  I’d like the focus to be mainly on cancer research & related topics.

The area of cancer research is so vast (pathology of cancers, molecular genetics of cancer, cell biology of cancer, cell cell signalling between cancer cells and other cancer cells or normal cells, metastasis) that there should be plenty to discuss without including general discussion on the individual topics (pathology, molecular genetics, cell biology, etc.).  I am not saying that discussion on any of the individual topics is not worthwhile; discussion on any of them would be extremely worthwhile.  But, if we want a newsgroup on cancer research then that is what the group should focus on and other newsgroups should be set up to discuss the individual topics, such as cell biology.  Of course, the amount of discussion on cancer-related topics depends on the interests of those who would participate in this newsgroup.  I realize that discussion in a cancer-type newsgroup may become generalized at times because cancer overlaps so many other topics, but if the group starts out too general then it (the newsgroup) may have no real focus.

To recap, perhaps more succinctly, I think a cancer research newsgroup is a great idea, but it shouldn’t include discussion in general on broad disciplines which include cancer research as only one aspect of
their total interests.